Carboplatin news

All news on Carboplatin (also known as Diammine[cyclobutane-1,1-dicarboxylato(2-)-O,O']platinum): plants, production capacities, investments and involved companies.

11 September 2026

Johnson & Johnson: RYBREVANT OS and tolerability updates at WCLC 2026

Final overall survival data for RYBREVANT plus chemotherapy in EGFR exon 20 insertions and tolerability updates for subcutaneous RYBREVANT FASPRO with prophylactic strategies.
8 September 2026

Amgen: IMDELLTRA plus Imfinzi improves overall survival in first‑line maintenance ES‑SCLC

Tarlatamab (IMDELLTRA) plus durvalumab showed statistically significant OS, PFS and ORR benefits versus durvalumab alone in Phase 3 DeLLphi‑305 for first‑line maintenance ES‑SCLC.
30 July 2026

Johnson & Johnson: FDA Priority Review for potential first-in-class subcutaneous RYBREVANT FASPRO in recurrent/metastatic HNSCC

OrigAMI-4 showed 42% response rate with >1/3 complete responses; FDA review shortened to ~6 months; drug targets EGFR and MET and is co-formulated with hyaluronidase.
22 June 2026

Boehringer Ingelheim launches three Phase III trials in hard-to-treat lung cancers

Three Phase III trials will test DLL3-targeting obrixtamig in SCLC and epNEC, and HER2 TKI zongertinib as adjuvant therapy in resectable HER2‑mutant NSCLC.
10 June 2026

Genentech: FDA grants Priority Review for Tecentriq plus chemotherapy in stage III dMMR/MSI‑H colon cancer

FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.
31 May 2026

Johnson & Johnson: RYBREVANT FASPRO shows durable responses in advanced head and neck cancer

Phase 1b/2 OrigAMI-4: subcutaneous amivantamab + hyaluronidase achieved 42% ORR (15% CR) in pretreated recurrent/metastatic HNSCC; median DOR not reached (11.8 mo FU); manageable safety.

Who will be producing Carboplatin in the future?

Find out with chemXplore Alpha

Learn more